DEF: ETHZilla Seeks Shareholder Approval for Key Governance & Equity Plans

Sentiment:

Proxy Statement for Special Meeting


ETHZilla Corporation calls a Special Meeting on October 7, 2025, to vote on electing a new director, approving multiple incentive plans, removing a Nasdaq exchange cap on convertible notes, and increasing authorized common stock.

Delay expectedThe Special Meeting may be adjourned if there are insufficient votes to approve key proposals, delaying critical corporate actions.If stockholder approval for the Nasdaq 20% Cap Removal Proposal is not obtained, the company is obligated to hold additional stockholder meetings semi-annually until approval is secured, incurring additional resources and delaying full utilization of the convertible notes.
Capital raiseThe company entered into a Securities Purchase Agreement on August 8, 2025, for senior secured convertible notes totaling $156,250,000.The company is seeking to increase its authorized common stock from 1 billion to 5 billion shares to provide flexibility for future financing and business purposes, including capital raises.Preliminary discussions are underway regarding potential options to raise capital, some of which may result in significant dilution to existing shareholders.The proposed 2025 Omnibus Incentive Plan, 2025 Supplemental Option Incentive Plan, and 2025 Second Supplemental Option Incentive Plan are designed to issue equity as compensation, which is a form of capital allocation and can impact capital structure.

Summary

  • A Special Meeting of Stockholders will be held virtually on October 7, 2025, at 9:00 am Pacific Time.
  • Stockholders will vote on electing Jason New as a Class II director.
  • Approval is sought for the ETHZilla Corporation 2025 Omnibus Incentive Plan, reserving an initial 50,000,000 shares with annual 10% evergreen increases.
  • Approval is sought for the ETHZilla Corporation 2025 Supplemental Option Incentive Plan, reserving 9,197,614 shares.
  • Approval is sought for the ETHZilla Corporation 2025 Second Supplemental Option Incentive Plan, reserving 1,814,221 shares.
  • Stockholders will vote on removing the Nasdaq 20% exchange cap on senior secured convertible notes issued on August 8, 2025, with a principal amount of $156,250,000, which could lead to a 21.6% dilution (45,355,587 shares).
  • A proposal to increase authorized common stock from 1 billion to 5 billion shares will be voted upon.
  • Amendments to the Certificate of Incorporation to remove obsolete provisions are also on the agenda.
  • The Board unanimously recommends voting FOR all proposals.
  • The record date for voting is August 20, 2025, with 164,447,345 shares of common stock outstanding.
  • Blair Jordan resigned as CEO, director, and Secretary on September 4, 2025, receiving a $1,350,000 cash payment and Volaro ownership in a separation agreement.
  • McAndrew Rudisill was appointed Chief Executive Officer on September 4, 2025, and Executive Chairman in August 2025.
  • Eric R. Van Lent was appointed Chief Accounting Officer in February 2025 and Secretary in September 2025.
  • Net loss decreased from $38.7 million in 2022 to $6.17 million in 2024.
  • The company settled litigation with Tyche Capital LLC and Ronald & Samantha Bauer, resulting in a $156,891 gain and cancellation of 2,385 common shares.
  • A settlement with AmTrust International Underwriters DAC involved a $250,000 cash payment and issuance of 509,707 common shares (valued at $575,000) by the company, resolving litigation and resulting in net reimbursements of $1,788,443 to the company after attorney fees.

Sentiment

Score: 4

Explanation: While the company is actively addressing governance and securing capital, the significant potential for dilution from multiple proposals (20% cap removal, 400% increase in authorized shares, multiple new incentive plans) and recent executive turnover create uncertainty. The reduction in net loss is positive, but the overall financial health and strategic direction are heavily reliant on these shareholder approvals and future capital raises, which carry substantial dilution risk.

Positives

  • The company has secured $156.25 million in senior secured convertible notes, indicating access to capital for its operations and ETH treasury strategy.
  • Net loss has significantly decreased from $38.7 million in 2022 to $19.9 million in 2023, and further to $6.17 million in 2024, showing improved financial performance.
  • Resolution of significant legal disputes with Tyche Capital LLC and Ronald & Samantha Bauer resulted in a gain of $156,891 and cancellation of 2,385 common shares.
  • The settlement with AmTrust International Underwriters DAC resolved ongoing litigation and resulted in net reimbursements totaling $1,788,443 to the company.
  • The Board is actively seeking to attract and retain talent through the proposed 2025 Omnibus Incentive Plan and two Supplemental Option Incentive Plans.
  • Appointment of experienced professionals like McAndrew Rudisill as CEO and Executive Chairman, Eric R. Van Lent as Chief Accounting Officer and Secretary, and Jason New as a director nominee strengthens management and governance.

Negatives

  • The potential for significant shareholder dilution is high, with the Nasdaq 20% Cap Removal Proposal allowing for conversion of 45,355,587 shares (21.6% dilution) and the Authorized Share Increase Proposal raising authorized common stock from 1 billion to 5 billion shares.
  • If the Nasdaq 20% Cap Removal Proposal is not approved, the company may be forced to repay convertible notes in cash, potentially limiting capital for business plans and ETH treasury strategy.
  • The company does not have a policy on equity ownership for executives and directors, which may lead to less direct alignment of management's wealth with long-term shareholder value.
  • Executive compensation includes substantial equity awards, making compensation values susceptible to stock price volatility.
  • Ongoing legal proceedings, such as the action against former executive Dr. Marlene Krauss (though partially settled), and potential collection attempts by Cambridge Capital Ltd. and Park Lane Capital, Ltd. for approximately $130,000, still pose risks.
  • The company has not historically used net loss as a performance measure for executive compensation, which could indicate a disconnect between executive incentives and profitability.

Risks

  • Shareholder dilution is a significant risk if the CN Nasdaq 20% Cap Removal Proposal and the Authorized Share Increase Proposal are approved, potentially impacting voting power and economic rights.
  • Stock price volatility may increase due to the potential issuance of a large number of shares from convertible note conversions and future capital raises.
  • The company faces capital constraints if the CN Nasdaq 20% Cap Removal Proposal is not approved, potentially forcing cash repayment of convertible notes and hindering business plans and ETH treasury strategy.
  • Failure to approve incentive plans could adversely impact the company's ability to attract, retain, and motivate highly skilled employees and consultants.
  • Ongoing legal proceedings and potential future claims, such as those from Cambridge Capital Ltd. and Park Lane Capital, Ltd., could result in financial liabilities and reputational damage.
  • The company's forward-looking statements are subject to risks and uncertainties, including the need for additional funding, changing government regulations, trial outcomes, and commercialization challenges, which could cause actual results to differ materially.

Future Outlook

The Board intends to use the additional authorized shares for future financing, strategic relationships, acquisitions, and to attract and retain talent. Future offering transactions may include common stock, warrants, or other convertible securities, structured to comply with Nasdaq stockholder approval requirements. The company is committed to holding additional shareholder meetings if necessary to obtain approval for proposals not passed on October 7, 2025. The company's future success is dependent on its ability to raise capital and effectively implement its ongoing business plans and ETH treasury strategy.

Management Comments

  • The Board of Directors believes that this leadership structure [combined Executive Chairman and CEO] is the most effective and efficient for the Company at this time.
  • Mr. Rudisill possesses detailed and in-depth knowledge of the issues, opportunities, and challenges facing the Company, and is thus best positioned to develop agendas that ensure that the Board of Directors time and attention are focused on the most critical matters.
  • Combining the Executive Chairman of the Board and CEO roles promotes decisive leadership, fosters clear accountability and enhances the Companys ability to communicate its message and strategy clearly and consistently to our stockholders, particularly during periods of turbulent economic and industry conditions.
  • The Board believes that having a strong independent Lead Director (Mr. Smith), best serves us and our stockholders at this time by leveraging executive leadership experience while providing effective independent oversight.
  • The reason for the adoption of the Omnibus Plan is solely to increase the shares available for issuances under our equity incentive plans in order for us to be able to issue additional equity incentive compensation awards for the purpose of attracting and retaining the best available personnel for positions of substantial responsibility, providing additional incentive to employees, directors and consultants, and promoting the success of our business.
  • The purpose of the Authorized Shares Increase Amendment is to provide the Board the ability to issue additional shares of common stock of the Company to enable the Company to complete transactions which the Board believes may be accretive to stockholders, including acquisitions, consulting and employment relationships and fund raisings.
  • If our stockholders do not approve this proposal, our financing alternatives may be limited by the lack of sufficient unissued and unreserved authorized shares of common stock, and stockholder value may be harmed by this limitation.
  • If our stockholders do not approve this proposal, we may not be able to access the capital markets, complete corporate collaborations, partnerships or other strategic transactions, attract, retain and motivate employees, and pursue other business opportunities integral to our growth and success.

Industry Context

The company's name change to ETHZilla Corporation and the mention of 'digital assets' and 'sustainable bitcoin mining' (in Jason New's background) strongly suggest a strategic pivot or significant involvement in the cryptocurrency and blockchain industry. The senior secured convertible notes being backed by Ether (ETH) collateral further reinforces this focus. The need for substantial capital raises and increased authorized shares is characteristic of high-growth or capital-intensive sectors like technology and digital assets, where rapid expansion and development require significant funding. The emphasis on equity incentive plans is also typical for competitive industries aiming to attract and retain top talent.

Comparison to Industry Standards

  • The filing does not provide specific industry benchmarks or comparable company data to assess results against global standards.
  • Jason New's experience with TeraWulf Inc. (Nasdaq: WULF), a digital asset technology company focused on sustainable bitcoin mining, provides an indirect comparable for the digital asset space, but no specific performance metrics are compared.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Executive Officer and Executive ChairmanBlair JordanMcAndrew Rudisill2025-09-04Blair Jordan's resignation and mutual separation agreement; McAndrew Rudisill's appointment.
Chief Accounting Officer and SecretaryOzan Pamir (as CFO and Secretary)Eric R. Van Lent2025-09-05Ozan Pamir's resignation; Eric R. Van Lent's appointment.
Chief Financial OfficerOzan Pamir2024-09-30Resignation.
Chief Financial OfficerOmar Jimenez2024-12-16Resignation.
Chief Scientific OfficerDr. Jonathan Rothbard2024-05-07Resignation and separation agreement.
Class II DirectorJason NewBoard nomination for election at the Special Meeting.
DirectorDr. James N. Woody2024-05-07Resignation.
DirectorDr. Sir Marc Feldmann2024-03-07Resignation.
DirectorJay Goodman2025-06-13Resignation and release agreement.
DirectorDr. Lawrence Steinman2025-08-04Resignation.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Board Leadership StructureThe Board maintains a combined Executive Chairman and Chief Executive Officer role (McAndrew Rudisill) complemented by a strong independent Lead Director (Ryan Smith) with robust, well-defined responsibilities.2025-02-04Aims to promote decisive leadership, clear accountability, and effective independent oversight, leveraging executive leadership experience while ensuring independent governance.
Clawback Policy AdoptionAdopted a Policy for the Recovery of Erroneously Awarded Incentive Based Compensation, mandating recovery of incentive-based compensation from current and former executive officers if an accounting restatement is required, regardless of misconduct. Applies to the three completed fiscal years preceding the restatement date.2023-10-02Enhances corporate accountability and aligns with SEC and Nasdaq rules, potentially reducing financial risk from misstated results.
Insider Trading/Anti-Hedging PoliciesMaintains an insider trading policy prohibiting derivative securities transactions (e.g., puts, calls, short sales) that profit from stock price decline for executive officers, directors, and employees. Discourages other hedging transactions and prohibits holding company securities in margin accounts or pledging as collateral without clear financial capability.2024-12-31Designed to promote compliance with insider trading laws, rules, and regulations, and align insider interests with shareholders by discouraging speculative trading against the company's stock.
Equity Ownership PolicyThe company currently does not have a formal policy on equity ownership for its directors and executive officers.May indicate less direct alignment of management and director wealth with long-term shareholder value compared to companies that mandate significant equity holdings.
Board Committee MembershipThe Audit, Compensation, and Nominating and Corporate Governance Committees are composed solely of independent directors. Stephen H. Shoemaker qualifies as an audit committee financial expert. Ryan Smith chairs the Nominating and Corporate Governance Committee and is Lead Independent Director. Andrew Suckling chairs the Compensation Committee.2025-08-01Ensures independent oversight of financial reporting, executive compensation, and corporate governance matters, enhancing accountability and compliance.

Legal Proceedings

  • The company settled legal action against former executive Dr. Marlene Krauss and KBL Affiliates on February 21, 2025, involving a $50,000 cash payment and issuance of 200,000 restricted common shares to Dr. Krauss, with mutual general releases and dismissal of court actions.
  • The company settled its action against Tyche Capital LLC and the action against Ronald Bauer & Samantha Bauer on June 30, 2024. This settlement resulted in the forgiveness of $81,720 in loans and $25,171 in accrued interest from the Bauer Defendants, exoneration of a $50,000 bond, mutual releases, and dismissal of both actions. The company recognized a gain of $156,891.
  • The company entered into a Confidential AmTrust Settlement Agreement and Release with AmTrust International Underwriters DAC on April 6, 2025, resolving ongoing litigation. The settlement involved a $250,000 cash payment and issuance of 509,707 common shares (valued at $575,000) by the company, with mutual broad releases and dismissal of the action. The company received net reimbursements totaling $1,788,443 from AmTrust and Freedom Specialty Insurance Company.
  • Ronald Bauer and Samantha Bauer agreed to indemnify the company against collection attempts by Cambridge Capital Ltd. and Park Lane Capital, Ltd. for approximately $130,000 in loans, though no assurance of indemnification is provided.

Related Party Transactions

  • The company has an Executive Consulting Agreement with EVL Consulting, LLC (owned by Eric R. Van Lent, Chief Accounting Officer) for CAO services at $8,000/month, extended through December 31, 2025.
  • A Statement of Work was entered into with EVL Consulting on September 2, 2025, for NetSuite OneWorld deployment for eight subsidiaries, for a fee of $60,000.
  • In connection with a PIPE Equity Financing, PCAO LLC (managed by CEO McAndrew Rudisill) received warrants to purchase 4,807,873 shares ($2.775 exercise price) and 957,002 shares ($3.445 exercise price) for strategic advisory services.
  • Pelagic Capital Advisors LLC (managed by CEO McAndrew Rudisill) and three advised beneficiary partnerships purchased 566,035 shares in the PIPE Offering.
  • New Island Advisors LLC (managed by director nominee Jason New) received Strategic Advisor Warrants to purchase 5,764,875 shares (4,807,873 at $2.775, 957,002 at $3.445) for strategic advisory services.
  • New Island Capital LLC (managed by director nominee Jason New) purchased 566,035 shares in the PIPE Offering.
  • Blair Jordan (former CEO) received a $1,350,000 cash payment and ownership of Volaro in a separation agreement on September 4, 2025.
  • A Settlement and Mutual Release Agreement with Elray Resources, Inc. (a greater than 5% stockholder) and Luxor Capital, LLC (both controlled by Anthony Brian Goodman, father of former director Jay Goodman) on April 28, 2025, involved the company acquiring 1,318,000 Elray Shares for $1 million, which were subsequently cancelled.
  • Prof. Sir Marc Feldmann (former Co-Executive Chairman) received 57,328 common shares and options to purchase 20,000 shares ($1.95 exercise price) in a separation agreement on September 5, 2024.
  • Prof. Jagdeep Nanchahal's consulting agreement includes a monthly fee of GBP 35,000 (from January 1, 2023) and prior bonuses paid in cash and shares.
  • Dr. Lawrence Steinman (former Executive Chairman) waived accrued salary amounts and resigned from the Board effective August 4, 2025.
  • Jay Goodman (former director) received a total payment of $98,333.33 in a release agreement on June 12, 2025.

Stakeholder Impact

  • Shareholders face potential significant dilution from the proposed increase in authorized shares and the removal of the Nasdaq 20% cap on convertible notes, which could impact their voting power and economic rights.
  • Employees, officers, directors, and consultants stand to benefit from new equity incentive plans designed to attract, retain, and motivate talent, but are also subject to clawback policies and insider trading restrictions.
  • Convertible note holders are secured by ETH and cash collateral, but their ability to convert notes into common stock is contingent on shareholder approval of the 20% cap removal, with potential for cash repayment if not approved.
  • The company's ability to execute its business plans and ETH treasury strategy is directly impacted by the outcome of the shareholder votes, particularly regarding capital raising flexibility and equity compensation.

Next Steps

  • Hold a virtual Special Meeting of Stockholders on October 7, 2025.
  • Stockholders to vote on electing Jason New as a Class II director.
  • Stockholders to vote on approving the 2025 Omnibus Incentive Plan.
  • Stockholders to vote on approving the 2025 Supplemental Option Incentive Plan.
  • Stockholders to vote on approving the 2025 Second Supplemental Option Incentive Plan.
  • Stockholders to vote on approving the removal of the Nasdaq 20% cap on convertible notes.
  • Stockholders to vote on increasing authorized common stock from 1 billion to 5 billion shares.
  • Stockholders to vote on approving amendments to the Certificate of Incorporation to remove obsolete provisions.
  • Stockholders to vote on adjourning the Special Meeting if necessary to solicit additional proxies.
  • If the 20% cap removal is not approved, the company must hold additional stockholder meetings semi-annually until approval is obtained.
  • File final voting results in a Current Report on Form 8-K within four business days following the Special Meeting.
  • The Board will continue to periodically review its leadership structure.
  • The company will continue to pursue business plans and ETH treasury strategy, which are dependent on capital raises.

Key Dates

DateDescription
2016-09-07Original Certificate of Incorporation filed (KBL Merger Corp. IV).
2017-06-02Amended and Restated Certificate of Incorporation filed.
2019-07-25Business Combination Agreement dated.
2019-08-21Employment Agreement with Dr. Rothbard (replaced prior agreement).
2020-11-06Business Combination consummated; Company name changed to 180 Life Sciences Corp.; Dr. Rothbard's employment agreement became effective.
2020-12-01Prof. Jagdeep Nanchahal Consultancy Agreement effective.
2021-02-25Amended and Restated Employment Agreement with Dr. James N. Woody effective November 6, 2020.
2021-02-25Employment Agreement with Ozan Pamir effective November 6, 2020.
2021-03-12Five-year warrants granted to Alliance Global Partners (expired unexercised).
2021-03-31First Nanchahal Amendment to Consultancy Agreement.
2021-04-15Company filed action against Tyche Capital LLC.
2021-08-23Company agreed to issue Prof. Nanchahal 161 shares of common stock for remaining Bonus 2.
2021-09-01Company initiated legal action against Dr. Marlene Krauss and KBL Affiliates.
2021-10-05Dr. Krauss and KBL Affiliates filed Answer, Counterclaims, and Third-Party Complaint.
2021-10-27Employment Agreement with Quan Anh Vu effective November 1, 2021.
2021-11-01Consulting Agreement with Lawrence Steinman effective.
2021-11-17Board increased Prof. Sir Marc Feldmann's salary to $225,000 per annum.
2021-12-01Bonus 1 (GBP 100,000) paid to Prof. Nanchahal.
2022-02-24Dr. Krauss filed amended Answer, Counterclaims, and Third-Party Complaint.
2022-03-01Prof. Nanchahal's monthly fee increased to GBP 23,000 (effective).
2022-04-19Dr. Krauss stipulated to dismiss counterclaims against Donald A. McGovern, Jr. and Lawrence Gold.
2022-04-27Amendment to consulting agreement with Prof. Sir Marc Feldmann (salary reduced to $0, accrued).
2022-04-27Amendment to consulting agreement with Dr. Steinman (salary reduced by $56,250, accrued).
2022-06-29AmTrust International Underwriters DAC filed declaratory relief action against the Company.
2022-08-25Court granted Company's Motion to Dismiss Individual Company Defendants and three counterclaims in Tyche action.
2022-09-20Company filed Answer and Counterclaims against AmTrust.
2022-11-22Company filed Motion for Summary Adjudication against AmTrust and Freedom.
2022-12-28Third Nanchahal Amendment (monthly fee increased to GBP 35,000 from Jan 1, 2023).
2023-01-15Mr. Vu's employment agreement terminated.
2023-05-03Court ordered AmTrust to pay Dr. Krauss's attorneys fees totaling $714,557.
2023-05-04Appellate Court affirmed ruling in Company's favor regarding Tyche's motion to vacate attachment order.
2023-09-04Options granted to James N. Woody (3,948 shares, $12.73 exercise price, expired unexercised).
2023-09-04Options granted to Jonathan Rothbard (790 shares, $12.73 exercise price, expired unexercised).
2023-11-07Board approved Clawback Policy, effective October 2, 2023.
2024-01-01Dr. Woody's base salary reduced by 50% to $245,000 (accruing).
2024-01-01Dr. Rothbard's base salary reduced by 50% to $100,000 (accruing).
2024-01-29Board determined no bonuses for management for 2022 or 2023, and no accruals for 2024.
2024-02-28Blair Jordan appointed to the Board.
2024-03-07Dr. Sir Marc Feldmann resigned from the Board.
2024-03-07Omar Jimenez appointed to the Board.
2024-03-07Ryan L. Smith appointed to the Board.
2024-04-16AmTrust paid $2.27 million in reimbursement of fees.
2024-05-07Dr. James N. Woody resigned as CEO and director, entered Separation Agreement.
2024-05-07Dr. Jonathan Rothbard resigned as Chief Scientific Officer, entered Separation Agreement.
2024-05-07Blair Jordan appointed Interim Chief Executive Officer.
2024-05-07Board set non-executive director compensation at $50,000/year + $15,000 for committee chair.
2024-05-09AmTrust paid a further $300,140 in reimbursement of fees.
2024-06-25Dr. Krauss filed Motion for partial summary judgment on share registration claim.
2024-06-30Settlement Agreement with Tyche and Bauer Defendants.
2024-09-04Sir Marc Feldmann Separation and Release Agreement.
2024-09-10Ozan Pamir resigned as CFO, effective September 30, 2024.
2024-09-11Omar Jimenez appointed CFO, effective September 30, 2024.
2024-09-23Freedom paid $125,000 in reimbursement of fees.
2024-10-24Jay Goodman appointed to the Board.
2024-12-03Stephen H. Shoemaker appointed to the Board.
2024-12-16Omar Jimenez resigned as CFO.
2025-01-30Tyche's 2,385 common shares cancelled.
2025-02-04Board approved Blair Jordan as CEO, increased compensation to $240,000/year.
2025-02-04Ryan Smith appointed Lead Independent Director, with an additional $20,000/year.
2025-02-05First Amendment to Separation and Release Agreement with Dr. Woody (terminated Change of Control Bonus, issued 43,166 restricted shares).
2025-02-05Voting Agreement with Dr. Woody, Company, and Blair Jordan.
2025-02-15Executive Consulting Agreement with Eric R. Van Lent and EVL Consulting effective.
2025-02-20Executive Consulting Agreement with Blair Jordan and Jordan Consulting (replaced prior).
2025-02-20Board approved grant of 65,000 Restricted Common Stock to non-executive directors (Smith, Goodman, Steinman, Shoemaker).
2025-02-21Mutual Settlement and General Release Agreement with Dr. Krauss and KBL IV Sponsor, LLC.
2025-03-27Elray Resources, Inc. converted 1,000,000 Series B Preferred Stock into 1,318,000 common shares.
2025-04-06Confidential AmTrust Settlement Agreement and Release effective.
2025-04-28Settlement and Mutual Release Agreement with Elray Resources, Inc. and Luxor Capital, LLC.
2025-04-28Voting Agreement with Elray, Company, and Blair Jordan.
2025-05-01McAndrew Rudisill served as founding and Managing Partner of Harbour Island, LLC (since April 2025).
2025-05-12Trial scheduled for Declaratory Relief Action against AmTrust.
2025-06-12Jay Goodman resigned from the Board effective June 13, 2025, entered Release Agreement.
2025-06-17Amended and Restated Executive Consulting Agreement with Mr. Jordan and Jordan Consulting (replaced prior).
2025-06-17Board approved accelerated vesting of 160,000 restricted common stock for Blair Jordan.
2025-06-17Board approved grant of stock options to Blair Jordan (410,000 shares) and Eric R. Van Lent (25,000 shares) at $0.9290 exercise price.
2025-06-17Board approved grant of stock options to Ryan Smith (255,000 shares), Stephen H. Shoemaker (165,000 shares), and Dr. Lawrence Steinman (110,000 shares) at $0.9290 exercise price.
2025-06-17Company issued 167,576 restricted common stock to Blair Jordan and 8,174 to Eric R. Van Lent.
2025-06-17Company issued 102,181 restricted common stock to Ryan Smith, 67,439 to Stephen H. Shoemaker, and 44,959 to Dr. Lawrence Steinman.
2025-07-11Board approved accelerated vesting of June 2025 Executive Shares.
2025-07-12Board approved accelerated vesting of June 2025 Executive Options and Non-Executive Director Options.
2025-07-27Elray exercised warrants for 3,000,000 shares on cashless basis, issued net 1,320,000 common shares.
2025-07-28Elray Shares issued.
2025-07-29Board approved discretionary cash bonuses for Blair Jordan ($191,250) and Eric Van Lent ($50,000) upon PIPE Offering closing.
2025-07-29Board approved annual compensation for non-executive directors increased to $350,000/year cash retainer.
2025-07-29Board approved grant of options to Blair Jordan (3,908,986 shares), Ryan Smith (3,908,986 shares), Stephen Shoemaker (919,761 shares), and outside legal counsel (459,881 shares) at $2.92 exercise price under 2025 Supplemental Option Incentive Plan (subject to shareholder approval).
2025-07-29First Amendment to Amended and Restated Executive Consulting Agreement with Mr. Jordan (fee increased to $450,000 if closing within 10 days).
2025-07-30EVL Consulting Agreement term through.
2025-07-31First Amendment to Consulting Agreement with Mr. Van Lent (extended term to Dec 31, 2025).
2025-07-31Dr. Lawrence Steinman resigned from the Board effective August 4, 2025.
2025-08-04PIPE Offering closed.
2025-08-04Dr. Lawrence Steinman's resignation from Board effective.
2025-08-05SEC filing (Current Report on Form 8-K).
2025-08-08Company entered Securities Purchase Agreement for senior secured convertible notes ($156,250,000 principal).
2025-08-08Board approved grant of options to Blair Jordan (771,044 shares), Ryan Smith (771,044 shares), Stephen Shoemaker (181,422 shares), and outside legal counsel (90,771 shares) at $3.01 exercise price under 2025 Second Supplemental Option Incentive Plan (subject to shareholder approval).
2025-08-11Schedule 13G filed by Peter Thiel.
2025-08-12Schedule 13G filed by Robert S. Pitts, Jr.
2025-08-18180 Life Sciences Corp. changed name to ETHZilla Corporation.
2025-08-18SEC filing (Current Report on Form 8-K).
2025-08-20Record date for Special Meeting.
2025-08-21SEC filing (Current Report on Form 8-K/A).
2025-08-21Voting Agreement with Dr. Krauss terminated automatically.
2025-08-26Board adopted 2025 Omnibus Incentive Plan (subject to stockholder approval).
2025-08-28Elray Shares cancelled; Mr. Jordan's voting proxy for Elray Shares terminated.
2025-09-02Statement of Work with EVL Consulting for NetSuite deployment.
2025-09-03Voting Agreement with Dr. Woody terminated.
2025-09-04Blair Jordan resigned as CEO, director, and Secretary; entered Separation and Release Agreement.
2025-09-04McAndrew Rudisill appointed Chief Executive Officer.
2025-09-05Proxy Statement first mailed to stockholders.
2025-09-05Eric R. Van Lent appointed Secretary.
2025-10-07Special Meeting of Stockholders.
2026-02-05Dr. Woody's Voting Agreement termination condition.
2026-03-15Deadline for payment of any bonus earned in 2025.
2026-04-28Elray's Voting Agreement termination condition.
2026-12-01Prof. Nanchahal's Consulting Agreement term through.
2027-12-31Jordan Consulting Agreement term through.
2035-01-01End of evergreen increase period for 2025 Omnibus Incentive Plan.

Recommendation

hold

The company is undergoing significant strategic and governance changes, including a pivot towards digital assets, substantial capital raises, and executive turnover. While the reduction in net loss and resolution of some legal disputes are positive, the potential for massive shareholder dilution from the proposed increase in authorized shares (from 1 billion to 5 billion) and the removal of the 20% Nasdaq cap on convertible notes (potentially adding 21.6% dilution) introduces considerable risk. Investors should hold to observe the outcome of the Special Meeting and the subsequent execution of the company's strategy, particularly regarding how the newly authorized shares and convertible notes are utilized and their actual dilutive impact. The company's ability to effectively integrate new management and leverage its digital asset strategy will be crucial.

Keywords

Proxy Statement, Special Meeting, Shareholder Vote, Corporate Governance, Equity Incentive Plan, Stock Options, Convertible Notes, Nasdaq Listing Rules, Authorized Shares, Share Dilution, Executive Compensation, Related Party Transactions, Legal Proceedings, ETHZilla, Capital Raise, Director Election, Digital Assets, Cryptocurrency

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.